0001209191-18-005827.txt : 20180129
0001209191-18-005827.hdr.sgml : 20180129
20180129161457
ACCESSION NUMBER: 0001209191-18-005827
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180125
FILED AS OF DATE: 20180129
DATE AS OF CHANGE: 20180129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cha Albert
CENTRAL INDEX KEY: 0001397906
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38356
FILM NUMBER: 18555670
MAIL ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
FORMER NAME:
FORMER CONFORMED NAME: CHA ALBERT
DATE OF NAME CHANGE: 20070427
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Menlo Therapeutics, Inc.
CENTRAL INDEX KEY: 0001566044
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 453757789
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4085 CAMPBELL AVENUE, SUITE 200
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-486-1416
MAIL ADDRESS:
STREET 1: 4085 CAMPBELL AVENUE, SUITE 200
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: Tigercat Pharma, Inc.
DATE OF NAME CHANGE: 20130104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-01-25
0
0001566044
Menlo Therapeutics, Inc.
MNLO
0001397906
Cha Albert
204 CARDINAL WAY, 2ND FLOOR
REDWOOD CITY
CA
94063
1
0
0
0
Common Stock
2018-01-25
4
P
0
258432
17.00
A
258432
I
By Vivo Capital Fund VIII, L.P.
Common Stock
2018-01-25
4
P
0
35686
17.00
A
35686
I
By Vivo Capital Surplus Fund III, L.P.
Common Stock
2018-01-29
4
C
0
2348550
A
2606982
I
By Vivo Capital Fund VIII, L.P.
Common Stock
2018-01-29
4
C
0
324306
A
359992
I
By Vivo Capital Surplus Fund III, L.P.
Common Stock
2018-01-29
4
C
0
917559
A
3524541
I
By Vivo Capital Fund VIII, L.P.
Common Stock
2018-01-29
4
C
0
126703
A
486695
I
By Vivo Capital Surplus Fund III, L.P.
Series B Preferred Stock
2018-01-29
4
C
0
6335215
0.00
D
Common Stock
2348550
0
I
By Vivo Capital Fund VIII, L.P.
Series B Preferred Stock
2018-01-29
4
C
0
874817
0.00
D
Common Stock
324306
0
I
By Vivo Capital Surplus Fund III, L.P.
Series C Preferred Stock
2018-01-29
4
C
0
2475118
0.00
D
Common Stock
917559
0
I
By Vivo Capital Fund VIII, L.P.
Series C Preferred Stock
2018-01-29
4
C
0
341784
0.00
D
Common Stock
126703
0
I
By Vivo Capital Surplus Fund III, L.P.
The reporting person is one of the managing members of Vivo Capital VII, LLC ("Vivo LLC"), which is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.
/s/ Stephen Thau as attorney-in-fact
2018-01-29